News
Now Ipsen and Forseen Biotechnology have an Exclusive Global Licensing Agreement for Antibody Drug Conjugate with First-in-Class Potential
Today Ipsen and Forseen announced an exclusive global licensing agreement for FS001 an antibody drug conjugate ( ADC) with first-in-class potential. FS001 targets an antigen
July 11, 2024
No Comments
